Clinical Trials | June 26, 2024
Imfinzi improved event-free survival and overall survival for bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Combined entity is better positioned to compete in increasingly competitive generics industry
The company will now explore a buyer for its manufacturing site and exit in due course
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Subscribe To Our Newsletter & Stay Updated
